Skip header and navigation

Refine By

6 records – page 1 of 1.

Anthropometrics and prognosis in diffuse large B-cell lymphoma: a multicentre study of 653 patients.

https://arctichealth.org/en/permalink/ahliterature282257
Source
Eur J Haematol. 2017 Apr;98(4):355-362
Publication Type
Article
Date
Apr-2017
Author
Mette Dahl Bendtsen
Peter Svenssen Munksgaard
Marianne Tang Severinsen
Eric Bekric
Christian Brieghel
Kristina Buchardi Nielsen
Peter de Nully Brown
Karen Dybkaer
Hans Erik Johnsen
Martin Bøgsted
Tarec Christoffer El-Galaly
Source
Eur J Haematol. 2017 Apr;98(4):355-362
Date
Apr-2017
Language
English
Publication Type
Article
Keywords
Aged
Antibodies, Monoclonal, Murine-Derived - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Body mass index
Body surface area
Cyclophosphamide - administration & dosage
Denmark
Disease-Free Survival
Doxorubicin - administration & dosage
Female
Humans
Lymphoma, Large B-Cell, Diffuse - drug therapy - mortality - pathology
Male
Middle Aged
Overweight
Prednisone - administration & dosage
Registries
Retrospective Studies
Survival Rate
Vincristine - administration & dosage
Abstract
The impact of body mass index (BMI) and body surface area (BSA) on survival in diffuse large B-cell lymphoma (DLBCL) is controversial. Recent studies show superior outcomes for overweight and obese patients.
A total of 653 R-CHOP(-like)-treated DLBCL patients were included in this retrospective cohort study. Patients, baseline clinicopathologic characteristics and treatment information were retrieved from the Danish Lymphoma Registry. Anthropometric measures were obtained from chemotherapy prescription charts.
Underweight (BMI
PubMed ID
27893172 View in PubMed
Less detail

Borderline Personality Disorder and Posttraumatic Stress Disorder at Psychiatric Discharge Predict General Hospital Admission for Self-Harm.

https://arctichealth.org/en/permalink/ahliterature276606
Source
J Trauma Stress. 2015 Dec;28(6):556-62
Publication Type
Article
Date
Dec-2015
Author
Liv Mellesdal
Rolf Gjestad
Erik Johnsen
Hugo A Jørgensen
Ketil J Oedegaard
Rune A Kroken
Lars Mehlum
Source
J Trauma Stress. 2015 Dec;28(6):556-62
Date
Dec-2015
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Bipolar Disorder - epidemiology - psychology
Borderline Personality Disorder - epidemiology - psychology
Comorbidity
Depressive Disorder, Major - epidemiology - psychology
Female
Hospitalization - statistics & numerical data
Hospitals, Psychiatric - statistics & numerical data
Humans
Inpatients - statistics & numerical data
Interview, Psychological
Male
Middle Aged
Norway - epidemiology
Random Allocation
Regression Analysis
Risk assessment
Risk factors
Self-Injurious Behavior - epidemiology - psychology
Stress Disorders, Post-Traumatic - epidemiology - psychology
Suicide - prevention & control - psychology - statistics & numerical data
Young Adult
Abstract
We investigated whether posttraumatic stress disorder (PTSD) was predictor of suicidal behavior even when adjusting for comorbid borderline personality disorder (BPD) and other salient risk factors. To study this, we randomly selected 308 patients admitted to a psychiatric hospital because of suicide risk. Baseline interviews were performed within the first days of the stay. Information concerning the number of self-harm admissions to general hospitals over the subsequent 6 months was retrieved through linkage with the regional hospital registers. A censored regression analysis of hospital admissions for self-harm indicated significant associations with both PTSD (? = .21, p
Notes
Erratum In: J Trauma Stress. 2016 Feb;29(1):10626915448
PubMed ID
26581019 View in PubMed
Less detail

Cannabis use is associated with 3years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample (N=1119).

https://arctichealth.org/en/permalink/ahliterature277445
Source
Schizophr Res. 2016 Jan;170(1):217-21
Publication Type
Article
Date
Jan-2016
Author
Siri Helle
Petter Andreas Ringen
Ingrid Melle
Tor-Ketil Larsen
Rolf Gjestad
Erik Johnsen
Trine Vik Lagerberg
Ole A Andreassen
Rune Andreas Kroken
Inge Joa
Wenche Ten Velden Hegelstad
Else-Marie Løberg
Source
Schizophr Res. 2016 Jan;170(1):217-21
Date
Jan-2016
Language
English
Publication Type
Article
Keywords
Adult
Age of Onset
Cannabis
Family
Female
Humans
Male
Marijuana Abuse - complications - epidemiology
Norway - epidemiology
Psychotic Disorders - complications - epidemiology
Regression Analysis
Schizophrenia - complications - epidemiology
Sex Factors
Young Adult
Abstract
Patients with schizophrenia spectrum disorders and substance use may have an earlier onset of illness compared to those without substance use. Most previous studies have, however, too small samples to control for confounding variables and the effect of specific types of substances. The present study aimed to examine the relationship between substance use and age at onset, in addition to the influence of possible confounders and specific substances, in a large and heterogeneous multisite sample of patients with schizophrenia spectrum disorders.
The patients (N=1119) were recruited from catchment areas in Oslo, Stavanger and Bergen, Norway, diagnosed according to DSM-IV and screened for substance use history. Linear regression analysis was used to examine the relationship between substance use and age at onset of illness.
Patients with substance use (n=627) had about 3years earlier age at onset (23.0years; SD 7.1) than the abstinent group (n=492; 25.9years; SD 9.7). Only cannabis use was statistically significantly related to earlier age at onset. Gender or family history of psychosis did not influence the results.
Cannabis use is associated with 3years earlier onset of psychosis.
PubMed ID
26682958 View in PubMed
Less detail

Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study.

https://arctichealth.org/en/permalink/ahliterature284737
Source
J Clin Oncol. 2017 Mar;35(7):778-784
Publication Type
Article
Date
Mar-2017
Author
Lasse Hjort Jakobsen
Martin Bøgsted
Peter de Nully Brown
Bente Arboe
Judit Jørgensen
Thomas Stauffer Larsen
Maja Bech Juul
Lene Schurmann
Linda Højberg
Olav Jonas Bergmann
Therese Lassen
Pär Lars Josefsson
Paw Jensen
Hans Erik Johnsen
Tarec Christoffer El-Galaly
Source
J Clin Oncol. 2017 Mar;35(7):778-784
Date
Mar-2017
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Antibodies, Monoclonal, Murine-Derived - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - administration & dosage - therapeutic use
Cyclophosphamide - administration & dosage
Denmark - epidemiology
Disease-Free Survival
Doxorubicin - administration & dosage
Female
Humans
Life expectancy
Lymphoma, Large B-Cell, Diffuse - drug therapy - mortality
Male
Middle Aged
Prednisone - administration & dosage
Remission Induction
Vincristine - administration & dosage
Young Adult
Abstract
Purpose The general outlook for patients with diffuse large B-cell lymphoma (DLBCL) in first remission is important information for patients and for planning post-treatment follow-up. The purpose of this study was to evaluate the survival of patients with DLBCL in remission compared with a matched general population. Methods A total of 1,621 patients from the Danish Lymphoma Registry who were newly diagnosed with DLBCL between 2003 and 2011 were included in this study. All patients were = 16 years of age at diagnosis and had achieved complete remission or complete remission unconfirmed after first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or R-CHOP-like therapy. Results The 5-year post-treatment DLBCL survival was inferior to survival in the matched general population (78%; 95% CI, 76 to 80; v 87%; standardized mortality ratio, 1.75; P
PubMed ID
28095160 View in PubMed
Less detail

Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.

https://arctichealth.org/en/permalink/ahliterature269527
Source
Am J Hematol. 2015 Nov;90(11):1041-6
Publication Type
Article
Date
Nov-2015
Author
Tarec Christoffer El-Galaly
Diego Villa
Musa Alzahrani
Jakob Werner Hansen
Laurie H Sehn
Don Wilson
Peter de Nully Brown
Annika Loft
Victor Iyer
Hans Erik Johnsen
Kerry J Savage
Joseph M Connors
Martin Hutchings
Source
Am J Hematol. 2015 Nov;90(11):1041-6
Date
Nov-2015
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Bone Marrow - pathology
Canada
Cyclophosphamide
Denmark
Doxorubicin
Female
Fluorodeoxyglucose F18
Humans
Lymphoma, Large B-Cell, Diffuse - diagnosis - drug therapy - mortality - pathology
Male
Middle Aged
Neoplasm Staging
Ovary - pathology
Pleura - pathology
Positron-Emission Tomography
Prednisone
Prognosis
Retrospective Studies
Survival Analysis
Tomography, X-Ray Computed
Vincristine
Abstract
18F-fluorodeoxyglucose PET/CT (PET/CT) is the current state-of-the-art in the staging of diffuse large B-cell lymphoma (DLBCL) and has a high sensitivity for extranodal involvement. Therefore, reassessment of extranodal involvement and the current prognostic indices in the PET/CT era is warranted. We screened patients with newly diagnosed DLBCL seen at the academic centers of Aalborg, Copenhagen, and British Columbia for eligibility. Patients that had been staged with PET/CT and treated with R-CHOP(-like) 1(st) line treatment were retrospectively included. In total 443 patients met the inclusion criteria. With a median follow-up of 2.4 years, the 3-year overall (OS) and progression-free survival (PFS) were 73% and 69%, respectively. The Ann Arbor classification had no prognostic impact in itself with the exception of stage IV disease (HR 2.14 for PFS, P2 extranodal sites, including HR 7.81 (P?3 sites. Bone/bone marrow involvement was the most commonly involved extranodal site identified by PET/CT (29%) and was associated with an inferior PFS and OS. The IPI, R-IPI, and NCCN-IPI were predictive of PFS and OS, and the two latter could identify a very good prognostic subgroup with 3-year PFS and OS of 100%. PET/CT-ascertained extranodal involvement in DLBCL is common and involvement of >2 extranodal sites is associated with a dismal outcome. The IPI, R-IPI, and NCCN-IPI predict outcome with high accuracy.
PubMed ID
26260224 View in PubMed
Less detail

Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.

https://arctichealth.org/en/permalink/ahliterature270756
Source
J Clin Oncol. 2015 Dec 1;33(34):3993-8
Publication Type
Article
Date
Dec-1-2015
Author
Tarec Christoffer El-Galaly
Lasse Hjort Jakobsen
Martin Hutchings
Peter de Nully Brown
Herman Nilsson-Ehle
Elisabeth Székely
Karen Juul Mylam
Viktoria Hjalmar
Hans Erik Johnsen
Martin Bøgsted
Mats Jerkeman
Source
J Clin Oncol. 2015 Dec 1;33(34):3993-8
Date
Dec-1-2015
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cohort Studies
Denmark - epidemiology
Female
Follow-Up Studies
Humans
Lymphoma, Large B-Cell, Diffuse - drug therapy - epidemiology - mortality - pathology
Male
Middle Aged
Neoplasm Staging
Prognosis
Remission Induction
Survival Rate
Sweden - epidemiology
Tomography, X-Ray Computed - methods
Young Adult
Abstract
Routine imaging for diffuse large B-cell lymphoma (DLBCL) in first complete remission (CR) is controversial and plays a limited role in detecting relapse. This population-based study compared the survival of Danish and Swedish patients with DLBCL for whom traditions for routine imaging have been different.
Patients from the Danish and Swedish lymphoma registries were included according to the following criteria: newly diagnosed DLBCL from 2007 to 2012, age 18 to 65 years, and CR after R-CHOP/CHOEP. Follow-up for Swedish patients included symptom assessment, clinical examinations, and blood tests at 3- to 4-month intervals for 2 years, with longer intervals later in follow-up. Imaging was only recommended when relapse was clinically suspected. Follow-up for Danish patients was similar but included routine imaging (usually computed tomography every 6 months for 2 years).
Danish (n = 525) and Swedish (n = 696) patients with DLBCL had comparable baseline characteristics. Cumulative 2-year progression rate after CR was 6% (95% CI, 4 to 9) for International Prognostic Index (IPI) = 2 versus 21% (95% CI, 13 to 28) for IPI > 2. Age > 60 years (hazard ratio [HR], 2.3; 95% CI, 1.6 to 3.4), elevated lactate dehydrogenase (HR, 2.3; 95% CI, 1.4 to 3.8), B symptoms (HR, 1.7; 95% CI, 1.1 to 2.5), and Eastern Cooperative Oncology Group performance status = 2 (HR, 1.8; 95% CI, 1.0 to 3.0) were associated with worse post-CR survival. Imaging-based follow-up strategy had no impact on survival, neither for all patients nor for IPI-specific subgroups.
DLBCL relapse after first CR is infrequent, and the widespread use of routine imaging in Denmark did not translate into better survival. This favors follow-up without routine imaging and, more generally, a shift of focus from relapse detection to improved survivorship.
Notes
Comment In: J Clin Oncol. 2015 Dec 1;33(34):3983-426438116
PubMed ID
26438115 View in PubMed
Less detail

6 records – page 1 of 1.